Comments on the Discussion Forum: Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection.
JSON
Smith ML, Sharma S, Singh TP
Scand J Immunol - (-) e13111 [2021-10-28; online 2021-10-28]
We read the excellent presentation by Rodriguez-Argente and coauthors and wish to add some thoughts to the discussion1 . The lactoperoxidase (LPO) system is actually the first line of mammalian, immunological defense against airborne bacterial and viral infections, including influenza and the respiratory syncytial virus (RSV)2,3 . This is not well known and some textbooks of immunology don't even mention this system.
PubMed 34709678
DOI 10.1111/sji.13111
Crossref 10.1111/sji.13111